Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

BACKGROUND & AIMS In patients with chronic hepatitis B virus (HBV) infection, persistent exposure to high concentrations of antigen can disrupt T-cell functions. It is not clear to what extent long-term suppression of HBV by nucleos(t)ide analogues can restore antiviral T-cell functions. We compared HBV-specific T-cell responses of patients treated with nucleos(t)ide analogues with those detected in other conditions of HBV control. METHODS We analyzed intracellular levels of interferon gamma, interleukin-2, and tumor necrosis factor α in HBV-specific T cells after 10 days of stimulation with peptides covering the overall HBV genotype D sequence and ex vivo with selected CD8 epitopes and the corresponding HLA-A2 dextramers. Findings from patients treated with nucleos(t)ide analogues who had complete (HBV DNA negative/antibody to hepatitis B surface antigen positive) or partial (HBV DNA negative/hepatitis B surface antigen positive) control of their infections were compared with those of patients with spontaneous or interferon alfa-induced resolution of acute or chronic infections, inactive HBV carriers, or untreated hepatitis B e antigen-negative patients with chronic infections. RESULTS Although HBV-specific T cells from nucleos(t)ide analogue-treated patients with complete control of infection were dysfunctional ex vivo, they had efficient responses after in vitro expansion. These responses were comparable to those of patients who spontaneously resolved acute HBV infection. Nucleos(t)ide analogue-treated patients who were HBV DNA negative but hepatitis B surface antigen positive had lower levels of T-cell responses but responses greater than those of untreated patients with chronic infection. CONCLUSIONS In vitro reactivity can be restored to T cells from patients with suppressed HBV infection following long-term treatment with nucleos(t)ide analogues, despite prolonged exposure to large loads of antigen. Immune therapies that increase the antiviral T-cell response might increase the likelihood of complete HBV control in patients undergoing long-term nucleos(t)ide analogue treatment.

[1]  P. Lampertico,et al.  Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. , 2012, Journal of hepatology.

[2]  G. Missale,et al.  Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection , 2012, Gut.

[3]  R. Ahmed,et al.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. , 2011, Immunity.

[4]  Lanjuan Li,et al.  Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. , 2011, Antiviral research.

[5]  Jian Sun,et al.  Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy , 2011, Virology Journal.

[6]  D. Vergani,et al.  Immune and Viral Profile from Tolerance to Hepatitis B Surface Antigen Clearance: a Longitudinal Study of Vertically Hepatitis B Virus-Infected Children on Combined Therapy , 2010, Journal of Virology.

[7]  J. Niu,et al.  Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil , 2010, Mediators of inflammation.

[8]  Jiyuan Zhang,et al.  Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment , 2010, PloS one.

[9]  M. Ostrowski,et al.  Comparison of Immune Restoration in Early versus Late Alpha Interferon Therapy against Hepatitis C Virus , 2010, Journal of Virology.

[10]  G. Gores,et al.  HEPATOLOGY: A home for hepatocellular cancer publications , 2009, Hepatology.

[11]  S. Chokshi,et al.  Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion , 2008, Hepatology.

[12]  A. Neumann,et al.  Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity , 2007, Antimicrobial Agents and Chemotherapy.

[13]  S. Lewin,et al.  The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection , 2007, Hepatology.

[14]  E. Kuipers,et al.  Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. , 2007, Virology.

[15]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[16]  A. Bertoletti,et al.  Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection , 2007, Journal of Virology.

[17]  E. Wherry,et al.  Low CD8 T-Cell Proliferative Potential and High Viral Load Limit the Effectiveness of Therapeutic Vaccination , 2005, Journal of Virology.

[18]  R. Carithers,et al.  Practice Guidelines : Evaluation of the Patient for Liver Transplantation , 2005 .

[19]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[20]  E. Wherry,et al.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. McMahon,et al.  [AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. , 2004, Romanian journal of gastroenterology.

[22]  E. Wherry,et al.  Memory CD8 T-Cell Differentiation during Viral Infection , 2004, Journal of Virology.

[23]  Geoffrey Dusheiko,et al.  Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy , 2004, Journal of Virology.

[24]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[25]  Antonio Bertoletti,et al.  Kinetics of the immune response during HBV and HCV infection , 2003, Hepatology.

[26]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[27]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[28]  J. Niu,et al.  Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies , 2011, Cellular and Molecular Immunology.